Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP)
T. King, W. Bradford, S. Castro-Bernardini, E. Fagan, I. Glaspole, M. Glassberg, E. Gorina, P. Hopkins, D. Kardatzke, L. Lancaster, D. Lederer, S. Nathan, C. Pereira, S. Sahn, R. Sussman, J. Swigris, P. Noble (San Francisco, Brisbane, Miami, Nashville, New York, Falls Church, Charleston, Summit, Denver, Los Angeles, United States Of America; Lima, Peru; Melbourne, Brisbane, Australia; Sao Paolo, Brazil)
Source: International Congress 2014 – IPF and surroundings
Session: IPF and surroundings
Session type: Oral Presentation
Number: 4629
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. King, W. Bradford, S. Castro-Bernardini, E. Fagan, I. Glaspole, M. Glassberg, E. Gorina, P. Hopkins, D. Kardatzke, L. Lancaster, D. Lederer, S. Nathan, C. Pereira, S. Sahn, R. Sussman, J. Swigris, P. Noble (San Francisco, Brisbane, Miami, Nashville, New York, Falls Church, Charleston, Summit, Denver, Los Angeles, United States Of America; Lima, Peru; Melbourne, Brisbane, Australia; Sao Paolo, Brazil). Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP). Eur Respir J 2014; 44: Suppl. 58, 4629
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: